CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Blood donation from convalescent donorWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug724 NHANES smell and taste tests Wiki 1.00

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D000370 Ageusia NIH 1.00
D000857 Olfaction Disorders NIH 0.38
D014777 Virus Diseases NIH 0.14
D045169 Severe Acute Respiratory Syndrome NIH 0.06
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0000224 Decreased taste sensation HPO 1.00
HP:0000458 Anosmia HPO 0.38

There is one clinical trial.

Clinical Trials


1 Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19

The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously for the treatment of severe SARS-CoV-2 infections.

NCT04351659 COVID-19 Other: Blood donation from convalescent donor

Primary Outcomes

Description: Success of SARS-CoV-2 specific T cell manufacturing is defined as production of >200,000 T cells per donor. The success rate will be summarized descriptively.

Measure: Success rate in production of SARS-CoV-2 specific T cells from convalescent donor

Time: Two weeks (The expected duration of donor participation is 2 weeks)


No related HPO nodes (Using clinical trials)